Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer And Taisho Reach Deal for Schizophrenia Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer joins Merck and AstraZeneca in pursuing metabotropic glutamate receptor agonist candidates.

You may also be interested in...

Merck, Addex Sign $700 Million Deal For Novel Schizophrenia Candidate

Firms collaborate to develop a metabotropic glutamate receptor 5 target, a possible pathway for treatment of schizophrenia.

AstraZeneca Will Take Over mGluR Program From NPS Pharmaceuticals For $30 Million

NPS says it will use the money to fund further development of late-stage candidates Preos and Gattex.

FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts